Relative IgG titres to specific viral proteins in acute and convalescent sera from patients with primary and recurrent genital herpes simplex virus type 2 (HSV-2) infections were determined using an immunoblot assay. Patients with recurrent genital infections generally had high titres of antibody reactive with two of the three major viral glycoproteins (gD and gG) as well as with several viral capsid proteins in both acute and convalescent sera. In contrast, patients experiencing primary genital HSV-2 infections exhibited marked differences in the polypeptide reactivity profiles of acute and convalescent sera. Of particular interest was the observation that the earliest and strongest antibody response was directed not against the viral glycoproteins but rather to an internal capsid protein(s) of HSV-2.
Polypeptide Specificity of the Early Antibody Response Following Primary and Recurrent Genital Herpes Simplex Virus Type 2 Infections
By R. EBERLE,* S.-W. MOU AND J. A. ZAIA Division of Pediatrics, City of Hope Medical Center, 1500 East Duarte Road, Duarte, California 91010, U.S.A. (Accepted 6 June 1984 SUMMARY Relative IgG titres to specific viral proteins in acute and convalescent sera from patients with primary and recurrent genital herpes simplex virus type 2 (HSV-2) infections were determined using an immunoblot assay. Patients with recurrent genital infections generally had high titres of antibody reactive with two of the three major viral glycoproteins (gD and gG) as well as with several viral capsid proteins in both acute and convalescent sera. In contrast, patients experiencing primary genital HSV-2 infections exhibited marked differences in the polypeptide reactivity profiles of acute and convalescent sera. Of particular interest was the observation that the earliest and strongest antibody response was directed not against the viral glycoproteins but rather to an internal capsid protein(s) of HSV-2.
It has long been known that the glycoproteins of herpes simplex virus type 1 (HSV-1) are expressed on the surface of both virions and infected cells (Olshevsky & Becker, 1972; Heine et al., 1972) . Not surprisingly, the glycoproteins of HSV have since been found to represent the major target antigens of such diverse immunological defence mechanisms as virus neutralization (Sim & Watson, 1973 : Powell et al., 1974 , antibody-dependent cellular cytotoxicity (Norrild et al., 1979) , natural killer cells (Bishop et al., 1983) , and cytotoxic T lymphocytes (Lawman et al., 1980; Carter et al., 1981) . On examination of anti-polypeptide antibody titres in human sera, we previously reported that while antibodies are present which recognize most infected cell proteins, the highest titred antibody populations were usually those directed against the viral glycoproteins (Eberle & Mou, 1983) . In this communication we examine the reactivity pattern of human sera following genital HSV-2 infections.
HEp-2 cells infected for 24 h with 5 to 10 p.f.u./cell were used to prepare antigen for immunoblotting as described previously (Eberle & Mou, 1983) . Infected cell antigens were electrophoresed on 8.6% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose. Antigen-impregnated strips of nitrocellulose were blocked with a 3o/o solution of bovine serum albumin prior to incubation with serum samples. After washing, bound IgG was detected with 125I-labelled Staphylococcus aureus Protein A and autoradiography. Anti-polypeptide antibody titres were determined by densitometric scanning of autoradiographs of immunoblots of multiple serum dilutions.
Immunoblot titrations of the polypeptide specificity ofanti-HSV IgG in an HSV-seronegative serum (patient no. 20) and acute and convalescent sera from another patient (no. 148) with recurrent genital herpes are shown in Fig. 1 . At the lowest serum dilution tested (1:20), HSVnegative sera exhibited very low levels of non-specific reactivity which was limited almost exclusively to the virion capsid proteins (Fig. 1 e) . In contrast, both acute and convalescent sera from the patient with recurrent HSV-2 infection showed high levels of reactivity with a number of HSV-2 polypeptides ( Fig. 1 c, d ). High titres of anti-polypeptide antibodies directed against the gG glycoprotein, VP5, and to a lesser extent the gD glycoprotein were found. High titres of antibody reactive with a single band of approx. 80000 (80K) mol. wt. were also present. This polypeptide appears to be antigenically related to the gG glycoprotein, since polyclonal anti-gG * Sera were titrated by solid-phase radioimmunoassay using HSV-2-infected cell antigen. Serum titres were taken as the highest dilution tested which gave /> 3 x binding levels obtained with HSV-negative sera.
t All patients were seronegative for HSV-l-specific antibodies in both acute and convalescent sera and had virologically confirmed HS¥-2 infections.
:~ A, Acute serum obtained on presentation of patient; C, convalescent serum obtained 2 to 3 weeks postpresentation.
§ Reciprocal of the highest serum dilution that gave specific binding to the designated infected cell polypeptide. Endpoint values were determined by analysis of densitometric scans of exposed autoradiographs as described previously (Eberle & Mou, 1983) . Since all of the polypeptides comprising the p40 antigen are antigenically related to one another, the anti-p40 titres have been expressed as the highest serum dilution reacting with the major 41K protein of the HSV-2 p40 complex. sera and monoclonal anti-gG antibodies both recognize it (Fig. 1 b; H. Su & R. J. Courtney, personal communication). In contrast to what has been reported for recurrent HSV-1 infections, high titres of antibody reactive with the gB glycoprotein of HSV-2 were not readily apparent when sera were reacted with HSV-2 antigen. However, high titres of antibody reactive with a series of proteins ranging from 38.5K to 50.5K similar to those described previously for HSV-1 (Eberle & Mou, 1983) were also present. These proteins have been identified as the intracellular form of the p40 capsid antigen first described by Heilman et al. (1979, 1981) Table 1 . These data demonstrate that anti-HSV antibodies in sera of HSV-2-immune individuals, as in HSV-l-immune persons, are primarily directed against the viral glycoproteins and the p40 antigen.
Blot titration of sera from patients with primary genital HSV-2 infections revealed an altogether different pattern of antibody immunoreactivity. Immunoblots of acute and convalescent sera from one patient (no. 73) with a primary genital HSV-2 infection are shown in Fig. 1 (f, g) . The acute serum contained high titres (>i 640) of antibody reactive with the p40 antigen of HSV-2. However, in contrast to sera from patients with recurrent disease, no antibodies specifically reactive with any other HSV-2 polypeptides, including the viral glycoproteins, were detectable in this serum sample. The convalescent serum (drawn 2.5 weeks later) contained antibodies reactive with a number of HSV-2 proteins including the major glycoproteins and VP5. Antibody titres to these polypeptides ranged from 20 to >~ 640 while anti-p40 titres remained high (/> 640). Results similar to these were obtained for all patients with primary genital infections which were examined and are summarized in Table 1 . Anti-p40 antibodies were invariably present and represented the highest-titred anti-polypeptide antibody population * Sera have been ordered based on their anti-p40 antibody titres until these reached 1:640 or greater; sera with anti-p40 titres /> 1:640 were ordered on anti-gG antibody titres. present in acute sera. These anti-p40 titres remained high in all convalescent sera being equal to or greater than those of antibodies directed against other viral protein antigens.
Short communication
Considerable variation was observed in the anti-polypeptide antibody titres in acute and convalescent sera pairs from different patients with primary infections. In all probability, this reflects differences in the time post-infection at which the acute sera were obtained from different individuals (acute sera were obtained when patients sought treatment for genital infections). If it is assumed that higher anti-HSV antibody titres will occur with increasing time post-infection, then this variation can be corrected for in an approximate manner by ordering the sera based on their anti-HSV antibody titres. The results presented in Table 2 are obtained by basing the ordering on anti-p40 antibody levels (this viral antigen is most useful in this respect since antibody to it is present in all but a few early acute sera) until high antibody titres are reached (/> 640) and thereafter on the rise in antibody titres to the gG glycoprotein. That such ordering is justified is supported by the fact that acute and convalescent serum pairs simultaneously fall into order as would be expected, i.e. as sera HS-65A and HS-81A precede serum HS-73A, so do sera HS-65C and HS-81C precede serum HS-73C. Tabulated in this form, it becomes immediately evident that (i) anti-p40 IgG antibodies appear prior to the occurrence of detectable concentrations of antibodies directed against any other viral polypeptide antigens and (ii) the titre of these anti-p40 antibodies remains high as antibodies to other polypeptides appear.
The results of these experiments demonstrate two previously unrecognized points regarding the development of the anti-HSV IgG antibody response following primary herpetic infections. First, the appearance of IgG directed against denaturation-resistant epitopes on different HSV polypeptides is a non-isochronous event in that anti-p40 antibodies are detectable in sera, often at very high concentrations, prior to the appearance of IgG antibodies directed against any other viral proteins. Thus, individual antigens comprising a complex antigenic entity such as an HSV virion or infected cell do not appear to be equal in their ability to elicit an immune response. Second, contrary to what might intuitively be expected, the viral glycoproteins do not appear to elicit either the earliest or the strongest antibody response immediately following primary genital HSV-2 infections. Explanation of these observations is difficult for several reasons. The viral glycoproteins are known to be expressed on the surface of both virions and infected cells and represent the majority of the viral surface antigens (Olshevsky & Becker, 1972; Heine et al., 1972) . Therefore, the viral glycoproteins would be expected to elicit a strong antibody response which, in time, they appear to do. Furthermore, the p40 antigen is an internal virion structural protein (Heilman et al., 1979; Preston et al., 1983; Braun et al., 1984) which is neither glycosylated nor expressed on the surface of infected cells. Why then should this antigen elicit such a strong antibody response?
One possible explanation may lie within the technique used to examine the IgG response. The blotted antigen with which the sera are reacted has been denatured by exposure to SDS, urea, mercaptoethanol and methanol. Therefore, immunoblot assays are restricted in sensitivity to the detection of antibodies reacting with denaturation-resistant (and thus presumably continuous) epitopes of the viral proteins. However, a similar early and strong response to the internal N protein of measles virus has been reported by Graves et al. (1984) who immune-precipitated non-denatured viral antigens with human sera. Thus, it is possible that despite its limitations, the immunoblot assay may to some degree reflect the immunoreactivity pattern of human sera with non-denatured antigens. Even should the immunoreactivity pattern of sera observed by immunoblotting not prove to be representative of their reactivity with non-denatured proteins, the results presented here remain interesting in that they do demonstrate that antibodies reactive with one subclass of antigenic determinants (denaturation-resistant) of the p40 proteins are produced prior to the appearance of antibodies reactive with similar determinants of other HSV proteins. Use of complementary assays employing non-denatured antigens will obviously be necessary to clarify the results presented here before their significance can be fully evaluated. Such studies are currently in progress.
